[go: up one dir, main page]

MX9203808A - Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. - Google Patents

Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.

Info

Publication number
MX9203808A
MX9203808A MX9203808A MX9203808A MX9203808A MX 9203808 A MX9203808 A MX 9203808A MX 9203808 A MX9203808 A MX 9203808A MX 9203808 A MX9203808 A MX 9203808A MX 9203808 A MX9203808 A MX 9203808A
Authority
MX
Mexico
Prior art keywords
liposomic
lipid
antineoplastic agents
drug content
high drug
Prior art date
Application number
MX9203808A
Other languages
English (en)
Inventor
Lawrence D Mayer
Marcel B Bally
Pieter R Cullis
Richard S Ginsberg
George N Mitilenes
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of MX9203808A publication Critical patent/MX9203808A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX9203808A 1987-03-05 1992-06-29 Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. MX9203808A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2215487A 1987-03-05 1987-03-05
US16455788A 1988-03-07 1988-03-07
US63601591A 1991-01-04 1991-01-04

Publications (1)

Publication Number Publication Date
MX9203808A true MX9203808A (es) 1992-07-01

Family

ID=27361803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203808A MX9203808A (es) 1987-03-05 1992-06-29 Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.

Country Status (2)

Country Link
US (4) US5616341A (es)
MX (1) MX9203808A (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US20040208922A1 (en) * 1995-06-07 2004-10-21 The Regents Of The University Of California Method for loading lipid like vesicles with drugs or other chemicals
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
CA2202103C (en) * 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
DE19639811A1 (de) * 1996-09-27 1998-04-02 Artur Herzog Dr Mesmer Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US20050031679A1 (en) * 1998-03-27 2005-02-10 Clemens Unger Method for producing liposomal formulations of active ingredients
US6849616B1 (en) 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
CN1636598A (zh) * 1998-03-27 2005-07-13 法麦希亚－厄普约翰公司 加强静脉内雌莫司汀磷酸盐作用的方法
DE19813773A1 (de) * 1998-03-27 1999-09-30 Clemens Unger Verfahren zur Herstellung von liposomalen Wirkstoffformulierungen
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
IL155291A0 (en) * 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
WO2002038128A1 (fr) * 2000-11-10 2002-05-16 Japan Science And Technology Corporation Procede de preparation d'une dispersion de microsome
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
EP1372664A1 (en) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2442539C (en) * 2001-03-27 2011-11-08 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
ATE538206T1 (de) * 2001-04-17 2012-01-15 Danisco Us Inc Verfahren zur bindung von enzym an einen träger unter verwendung kationischer copolymere und damit hergestelltes produkt
US7044911B2 (en) * 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7238367B2 (en) * 2001-10-03 2007-07-03 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7184663B2 (en) * 2002-05-29 2007-02-27 Fujitsu Limited Optical ring network with hub node and method
BRPI0313191A2 (pt) * 2002-08-02 2016-11-08 Transave Inc composição e processo para produzir um agregado de platina e formulação farmacêutica
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
HUE025491T2 (en) * 2002-10-29 2016-04-28 Insmed Inc Delayed release of anti-infective agents
CN101229127B (zh) * 2002-11-26 2012-10-10 吉里德科学公司 脂质体制剂
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1596840A1 (en) * 2003-02-12 2005-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier
CA2536612A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US20060079463A1 (en) * 2003-05-20 2006-04-13 Zhong Hong J Anticancer compositions comprising methenamine
EP1729786A4 (en) * 2004-03-18 2008-03-26 Transave Inc ADMINISTRATION OF CISPLATIN BY INHALATION
KR101245990B1 (ko) * 2004-03-26 2013-03-20 테루모 가부시키가이샤 리포솜 제제
JP2007530639A (ja) * 2004-04-02 2007-11-01 イタルファルマコ，ソシエダ アノニマ リポソーム製剤
CA2564542C (en) 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101223366B1 (ko) 2004-05-03 2013-01-16 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
FR2873292B1 (fr) * 2004-07-23 2008-05-30 Jean Noel Colombani Composes et methodes pour controler la prise d'alcool
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
JP4638500B2 (ja) 2004-10-06 2011-02-23 ビーシー キャンサー エージェンシー 治療剤を封入するためのリポソームからなる組成物及び治療剤のリポソーム内での保持性を高めるための方法
ES2339577T3 (es) * 2004-10-18 2010-05-21 Polymun Scientific Immunbiologische Forschung Gmbh Composicion liposomal que contiene un principio activo para la relajacion de la musculatura lisa, preparacion de dicha composicion y su uso terapeutico.
JP4990786B2 (ja) 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
AU2006209335A1 (en) * 2005-01-18 2006-07-27 National University Corporation Hokkaido University Method for coating particle with lipid film
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
EP1959961A2 (en) * 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR CONVECTION-REINFORCED RELEASE OF NEUROTHERAPEUTICS WITH HIGH MOLECULAR WEIGHT
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
EP2076244B1 (en) * 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) * 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2008073195A2 (en) * 2006-11-08 2008-06-19 Duke University Method for activation of oxazaphosphorines
RU2009133447A (ru) * 2007-02-09 2011-03-20 Пониард Фармасьютикалз, Инк. (Us) Дозированная форма пикоплатина
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008137717A1 (en) * 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20120003294A1 (en) 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
US9078812B2 (en) * 2007-12-06 2015-07-14 The Bay Zoltan Foundation For Applied Research Particulate drug carriers as desensitizing agents
WO2009099651A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
WO2009121629A1 (en) * 2008-04-04 2009-10-08 Medigene Ag Solubilisation method
WO2010034837A1 (en) * 2008-09-26 2010-04-01 Phares Pharmaceutical Research N.V. Method of solubilising biologically active compounds
EP2344133B1 (en) 2008-10-07 2019-06-26 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same
US8524783B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524784B2 (en) * 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
EP2682106A1 (en) 2012-07-03 2014-01-08 Phares Pharmaceutical Research N.V. Method of solubilizing biologically active compounds
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
RU2675859C2 (ru) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
AU2015258947B2 (en) 2014-05-15 2020-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
CA2962709C (en) 2014-08-04 2023-09-19 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
NZ741291A (en) 2015-10-16 2022-10-28 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US10064417B2 (en) 2015-12-10 2018-09-04 Janssen Pharmaceutica Nv Milk filtration devices and methods for filtering
CN110381929A (zh) 2016-06-13 2019-10-25 阿森迪亚制药有限责任公司 卡维地洛分散系统的肠胃外缓释传递
RU2756837C2 (ru) * 2016-09-09 2021-10-06 Айрисис, Инк. Липосомальные противоопухолевые композиции
AU2018307509B2 (en) 2017-07-24 2021-04-29 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CA3098573A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
WO2020056104A1 (en) * 2018-09-14 2020-03-19 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
CN116601150A (zh) 2020-07-28 2023-08-15 爵士制药爱尔兰有限公司 稠合双环raf抑制剂及其使用方法
JP2023535595A (ja) 2020-07-28 2023-08-18 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式ｒａｆ阻害剤のキラル合成
CN115364218A (zh) 2021-05-21 2022-11-22 杭州高田生物医药有限公司 一种特定药脂比的药物组合物在抗肿瘤中的应用
JP2024526791A (ja) 2021-07-16 2024-07-19 セレーター ファーマシューティカルズ インコーポレイテッド リポソーム製剤の調製方法
CN118662446A (zh) * 2024-07-19 2024-09-20 辽宁大学 一种双药共载脂质体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962429A (en) * 1973-08-01 1976-06-08 Chugai Seiyaku Kabushiki Kaisha Method for reducing side effects of aminoglycoside antibiotics and composition therefor
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (es) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4193983A (en) * 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
AU530415B2 (en) * 1978-06-02 1983-07-14 International Standard Electric Corp. Integrated circuits
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3068743D1 (en) * 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4419348A (en) * 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
WO1983003383A1 (en) * 1982-03-29 1983-10-13 Liposome Co Inc Stable plurilamellar vesicles
US4460689A (en) * 1982-04-15 1984-07-17 Merck & Co., Inc. DNA Cloning vector TG1, derivatives, and processes of making
US4551288A (en) * 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
EP0153955A1 (en) * 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
CA1264668C (en) * 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
CA1270198C (en) * 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US4622188A (en) * 1984-12-21 1986-11-11 E. I. Du Pont De Nemours And Company Method for manufacturing liposomes
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5047245A (en) * 1985-07-26 1991-09-10 The Liposome Company, Inc. Novel composition for targeting, storing and loading of liposomes
GB8516859D0 (en) * 1985-07-03 1985-08-07 Secretary Trade Ind Brit Cam follower mechanisms
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
AU617678B2 (en) * 1987-05-22 1991-12-05 Liposome Company, Inc., The Prostaglandin-lipid formulations

Also Published As

Publication number Publication date
US5744158A (en) 1998-04-28
US6083530A (en) 2000-07-04
US5795589A (en) 1998-08-18
US5616341A (en) 1997-04-01

Similar Documents

Publication Publication Date Title
MX9203808A (es) Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
DE3863963D1 (de) Pharmazeutische zusammensetzungen.
DE68911473D1 (de) Arzneimittelformulierungen.
NO890283L (no) Legemiddel-avgivelsessystem for forbedret opptak.
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
FI885543L (fi) Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor.
FI922364A0 (fi) Farmaceutiska kompositioner.
FI901102A0 (fi) Farmaceutiska kompositioner.
IT8619625A0 (it) Composizioni farmaceutiche per inalazione.
DE3586545D1 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
NO912799L (no) Foradditiver for droevtyggere.
NO882897L (no) Avleveringssystem for legemidler.
FI900035A0 (fi) Tiazolfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
FI874020A0 (fi) Tetrahydrokinolinderivat, foerfarande foer deras framstaellning, deras anvaendning och dessa innehaollande farmaceutiska preparat.
FI883673A0 (fi) Farmaceutiska kompositioner.
FI883251A0 (fi) Substituerade bensimidazoler, foerfarande foer deras framstaellnig, dessa innehaollande farmaceutiska preparat och deras anvaendning.
FI884545A0 (fi) Farmaceutisk komposition, som innehaoller avsvaellande piperidinoalkanolfoereningar.
IT8722501A0 (it) Formulazioni farmaceutiche per somministrazione transdermica.
DE3873011D1 (de) Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate.
FI870293A0 (fi) 8 -acylaminoergoliner, deras framstaellning och dessa innehaollande farmaceutiska kompositioner.
FI882965A0 (fi) Aminocyklopentyletrar och deras framstaellning och farmaceutiska preparat.
FI881238A7 (fi) Farmaceutisk beredning.
IT8719700A0 (it) 2-tiometil-sostituite-piridine, metodo per la loro preparazione e composizioni farmaceutiche che le contengono.
DE3866789D1 (de) Pharmazeutische zusammensetzungen.